Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative mega campuses in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of September 30, 2024, Alexandria has a total market capitalization of $33.1 billion and an asset base in North America that includes 41.8 million RSF of operating properties, 5.3 million RSF of Class A/A+ properties undergoing construction, and one committed near-term project expected to commence construction in the next two years. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

Alexandria Real Estate Equities Inc.

The SPDR S&P 500 ETF Trust ($SPY) was down 0.57% today, March 13, as investors were concerned about the escalating geopolitical conflict and its im...

Why Is the SPY ETF Down Today, 3/13/2026?

Mare Engineering Group SpA ( ($IT:MARE) ) has issued an update. Mare Group S.p.A., an Italian high-tech engineering hub listed on Euronext Growth M...

Mare Group Exits Eles Stake, Redirects Capital to New Growth Plans

Aecon Group Inc. ( ($TSE:ARE) ) just unveiled an update. Aecon Group Inc. has launched a $150 million bought deal offering of 3,822,000 common shar...

Aecon Launches $150 Million Bought Deal Share Offering to Bolster Balance Sheet

The SPDR S&P 500 ETF Trust ($SPY) fell 0.16% today, March 10, as investors reacted to rising Treasury yields, increased volatility, and concerns th...

Why Is the SPY ETF Down Today, 3/10/2026?

In a report released yesterday, Sabahat Khan from RBC Capital maintained a Hold rating on Aecon Group Inc., with a price target of C$41.00. The com...

RBC Capital Sticks to Its Hold Rating for Aecon Group Inc. (ARE)

The SPDR S&P 500 ETF Trust ($SPY) rose 0.88% today, March 9, with support from a pullback in oil prices and easing geopolitical tensions. Important...

Why Is SPY ETF Up Today, 3/9/2026?

Daré Bioscience ( ($DARE) ) has issued an announcement. On March 6, 2026, Daré Bioscience completed the second closing of its previously announced ...

Daré Bioscience Completes Second Closing of Regulation A Offering

The latest update is out from Aecon Group Inc. ( ($TSE:ARE) ). Aecon Group’s utilities subsidiary has moved to expand its U.S. electrical utility s...

Aecon Utilities Buys Duna Services and Stake in KNX to Boost U.S. Power Infrastructure Business

Aecon Group Inc. (($TSE:ARE)) has held its Q4 earnings call. Read on for the main highlights of the call. Aecon Group Inc.’s latest earnings call p...

Aecon Group Inc. Signals Strong Turnaround in Earnings Call

An update from Aecon Group Inc. ( ($TSE:ARE) ) is now available. Aecon Group Inc. has appointed veteran nuclear and power executive Jeff Lyash to i...

Aecon Adds Veteran Nuclear and Power Executive Jeff Lyash to Board

Aecon Group Inc. ( ($TSE:ARE) ) has shared an update. Aecon Group Inc., together with partners Pomerleau and Stantec, has signed an agreement with ...

Aecon-Led Partnership Secures Key Role in Arctic Over-the-Horizon Radar Project

Goldman Sachs sees a short-term pressure on earnings of asset managers as retail investors flee private credit funds.


BLK, BX, APO: Retail Investors’ Fund Exit Roils $3.5T Private Credit Market — What’s Next?

Analysts have been eager to weigh in on the Financial sector with new ratings on Ares Management (ARES – Research Report), TPG (TPG – Research Repo...

Analysts Offer Insights on Financial Companies: Ares Management (ARES), TPG (TPG) and TransUnion (TRU)

Daré Bioscience ( ($DARE) ) has provided an update. On March 2, 2026, Daré Bioscience, Inc. made an updated corporate presentation available to inv...

Daré Bioscience Updates Investor Presentation Under Regulation FD

Mare Engineering Group SpA ( ($IT:MARE) ) just unveiled an announcement. Mare Group has received a precautionary court order from the Court of Peru...

Mare Group Hit by Court Order Blocking Voting Rights in Eles Meeting

Mare Engineering Group SpA ( ($IT:MARE) ) has provided an announcement. Mare Group, a high-tech engineering firm listed on Euronext Growth Milan, f...

Mare Group Challenges Eles Board Move in Xenon Takeover Bid

Alexandria Equities ( ($ARE) ) has issued an announcement. The filing from Alexandria Equities offers no specific description of its industry, prod...

Alexandria Equities Reports New Direct Financial Obligation

Ultragenyx ($RARE) common stock investors have filed a legal claim alleging the company made misleading statements regarding its Phase 3 clinical t...

Ultragenyx Pharmaceutical Faces Investor Lawsuit Following Study Failures and Stock Decline

In a report released on February 20, Chris Murray from ATB Cormark Capital Markets maintained a Hold rating on Aecon Group Inc., with a price targe...

ATB Cormark Capital Markets Sticks to Their Hold Rating for Aecon Group Inc. (ARE)

Mare Engineering Group SpA ( ($IT:MARE) ) just unveiled an announcement. Mare Group S.p.A., an engineering company listed on Euronext Growth Milan ...

Mare Group Moves to Reshape Governance at Eles Ahead of Shareholders’ Meeting

Barclays analyst maintained a Hold rating on Alexandria Equities on February 17. The company’s shares closed yesterday at $54.41. Currently, the an...

Barclays Reaffirms Their Hold Rating on Alexandria Equities (ARE)

In a report released today, Laura Chico from Wedbush maintained a Hold rating on Ultragenyx Pharmaceutical, with a price target of $25.00. Accordin...

Wedbush Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ultragenyx Pharmaceutical (RARE – Research Report) a...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Investors are closely monitoring Ultragenyx Pharmaceutical ($RARE) after a lawsuit was filed alleging the company misrepresented the potential of i...

Ultragenyx Pharmaceutical Faces Lawsuit Following Clinical Trial Disclosures

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Baxter International (BAX – Research Report) and U...

Analysts Offer Insights on Healthcare Companies: Baxter International (BAX) and Ultragenyx Pharmaceutical (RARE)

In a report released today, from Goldman Sachs maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $61.00. In addition to ...

Current Quarter	$1.73	Next Quarter	$1.62
Current Year	$6.4	Next Year	$6.06
QoQ Growth	-6.4%	YoY Growth	-5.3%
3Y EPS CAGR	-22.3%	Target Price	$60.07
Consensus	Buy	Upside	+24.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARE	$48.41	-3.66%	2.28M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ARE	$48.41	-3.7%	2.28M
3
4
5
6

ARE

ARE

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Alexandria Real Estate Equities Inc. Data in Excel

Get Alexandria Real Estate Equities Inc. Data in Excel